๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immune Checkpoint Inhibitors
Clinical trial register · China

Immune Checkpoint Inhibitors Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 4 Beijing 2 Nanning 2 Changsha 2 Chengdu 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin4 Beijing2 Nanning2 Changsha2 Chengdu1
All 11 locations
Target enrolment
to

Immune Checkpoint Inhibitors trials in China

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
NCT07670715Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-07-01
Not yet open
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS
NCT07579247HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection
Shanghai Public Health Clinical Center
Phase 1/2
50
Shanghai
2026-05
Not yet open
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
NCT07372079Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-05
Not yet open
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
NCT07132008Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University
Phase 3
94
Nanning
2025-10-01
Not yet open
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
Peking Union Medical College Hospital
Phase 2
65
Beijing
2025-08-30
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Recruiting
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
NCT07034326Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors
Kong Fanming
Phase 2/3
405
Tianjin
2025-01-01
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Active, closed
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT06576921Stomach Neoplasms, Immune Checkpoint Inhibitors
Xijing Hospital
Phase 2
116
Shijiazhuang, Xi'an, Tianjin
2024-11-15
Recruiting
The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
NCT06975384Lung Cancer, Sleep Disturbance, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
Second Xiangya Hospital of Central South University
Observational
1,270
Changsha
2024-11-01
Active, closed
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
First Hospital of China Medical University
Observational
97
Shenyang
2024-08-16
Active, closed
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NCT06124378Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2023-11-13
Recruiting
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
NCT07512518Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors
Peking Union Medical College Hospital
Observational
66
Beijing
2023-02-20
Recruiting
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
NCT05477979Lung Cancer, Psychological Stress, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
Second Xiangya Hospital of Central South University
Observational
750
Changsha
2020-06-01
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/immune-checkpoint-inhibitors

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Immune Checkpoint Inhibitors.

How many Immune Checkpoint Inhibitors trials are recruiting in China?

6 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immune Checkpoint Inhibitors), 14 studies
PhaseStudiesRecruitingShare
Phase 27250%
Observational4328.6%
Phase 1/2107.1%
Phase 2/3117.1%
Phase 3107.1%

Most active sponsors

Lead sponsors with the most studies (Immune Checkpoint Inhibitors)
Lead sponsorStudiesRecruiting
First Affiliated Hospital of Guangxi Medical University20
Peking Union Medical College Hospital21
Second Xiangya Hospital of Central South University22
Tianjin Medical University Cancer Institute and Hospital20
First Hospital of China Medical University10
Kong Fanming11
Shanghai Public Health Clinical Center10
Sichuan University11
Sun Yat-sen University11
Xijing Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.